It was noted that by day 9 and before the second dose of NKTR-214 or IL-2, a substantial decrease in the BLI signal was observed in spleen and tumor, independently of the treatment (Fig. 2b, c and Supplementary Fig. 5a), consistent with a q9d dosing schedule. The gene discussed is NKTR; the disease is neoplasm.